Carmat S.A. (CKMTF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Carmat S.A. (CKMTF) with AI Score 61/100 (Hold). Carmat S. A. is a French medical device company specializing in the design and development of a total artificial heart. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Carmat S.A. (CKMTF) Healthcare & Pipeline Overview
Carmat S.A., founded in 2008, focuses on developing and marketing the world's only total artificial heart, addressing a critical unmet need in end-stage heart failure. With a negative profit margin of -734.3%, the company is pre-profitability, relying on technological innovation and regulatory approvals for future growth in the medical devices sector.
Investment Thesis
Carmat S.A. presents a high-risk, high-reward investment opportunity centered on its innovative total artificial heart (TAH). The company's value hinges on successful clinical trials, regulatory approvals, and eventual commercial adoption of its device. Key value drivers include expansion into new geographic markets and demonstration of long-term device efficacy and patient survival. Upcoming catalysts include ongoing clinical trial results and potential partnerships with larger medical device companies. The investment thesis is tempered by the company's current lack of profitability (P/E of -0.04 and a profit margin of -734.3%) and the inherent risks associated with medical device development and regulatory pathways. The company's beta of 1.38 indicates higher volatility than the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Carmat S.A. is focused on the development of a total artificial heart (TAH) addressing end-stage biventricular heart failure.
- The company is headquartered in France and operates internationally, seeking regulatory approvals and partnerships.
- Carmat's TAH is designed to mimic the function of a natural heart, providing pulsatile flow and autoregulation.
- The company's market capitalization is $0.09 billion, reflecting its early stage and growth potential.
- Carmat's profit margin is -734.3%, indicating significant ongoing investment in research and development.
Competitors & Peers
Strengths
- Innovative total artificial heart technology.
- Potential to address a significant unmet medical need.
- Strong intellectual property protection.
- Experienced management team.
Weaknesses
- High development costs.
- Regulatory hurdles.
- Limited clinical data.
- Lack of profitability.
Catalysts
- Upcoming: Results from ongoing clinical trials of Carmat's total artificial heart will provide crucial data on its safety and efficacy.
- Upcoming: Potential regulatory approvals in new geographic markets, such as the United States, could significantly expand the company's market reach.
- Ongoing: Development of strategic partnerships with leading hospitals and cardiac centers will facilitate the adoption of Carmat's technology.
- Ongoing: Continued innovation and development of next-generation artificial heart technologies will maintain the company's competitive edge.
- Ongoing: Positive media coverage and increased awareness of Carmat's technology can drive investor interest and market demand.
Risks
- Potential: Clinical trial failures or negative data could significantly impact the company's prospects.
- Potential: Regulatory delays or rejections could delay or prevent the commercialization of Carmat's technology.
- Ongoing: Competition from established medical device companies could limit Carmat's market share.
- Ongoing: High development and manufacturing costs could strain the company's financial resources.
- Ongoing: Limited reimbursement coverage from healthcare providers and insurance companies could hinder adoption of Carmat's technology.
Growth Opportunities
- Expansion into the United States market represents a significant growth opportunity for Carmat. Obtaining FDA approval for its total artificial heart would allow the company to access the large and lucrative U.S. market. This expansion would require successful completion of clinical trials in the U.S. and the establishment of a robust sales and marketing infrastructure. The timeline for this expansion is dependent on regulatory approval, but could potentially occur within the next 3-5 years.
- Securing reimbursement agreements with healthcare providers and insurance companies is crucial for driving adoption of Carmat's total artificial heart. Positive clinical trial data demonstrating the cost-effectiveness of the device compared to existing treatments will be essential for negotiating favorable reimbursement terms. This process is ongoing and will likely continue over the next several years as the company gathers more data and expands its market presence.
- Developing strategic partnerships with leading hospitals and cardiac centers can accelerate the adoption of Carmat's total artificial heart. These partnerships can provide access to key opinion leaders, facilitate clinical trials, and establish centers of excellence for training and device implantation. Building these relationships is an ongoing process that will be critical for the company's long-term success.
- Expanding the indications for Carmat's total artificial heart to include a broader range of heart failure patients could significantly increase the addressable market. This would require further clinical trials to demonstrate the safety and efficacy of the device in different patient populations. This expansion could potentially occur within the next 5-7 years, depending on the results of ongoing research and development efforts.
- Developing next-generation versions of its total artificial heart with improved features and functionality can help Carmat maintain its competitive edge. This could include enhancements to the device's biocompatibility, durability, and ease of implantation. Continuous innovation is essential for staying ahead of the competition and meeting the evolving needs of patients and clinicians. This is an ongoing process that will drive the company's long-term growth.
Opportunities
- Expansion into new geographic markets.
- Development of new applications for its technology.
- Strategic partnerships with leading hospitals.
- Increasing awareness of heart failure and the need for advanced therapies.
Threats
- Competition from established medical device companies.
- Technological obsolescence.
- Changes in regulatory requirements.
- Economic downturns.
Competitive Advantages
- Proprietary total artificial heart technology.
- Patents protecting its device design and functionality.
- First-mover advantage in the total artificial heart market.
- Clinical data supporting the safety and efficacy of its device.
About CKMTF
Carmat S.A., established in 2008 and headquartered in Vélizy-Villacoublay, France, is a pioneering medical device company dedicated to creating a solution for patients with end-stage biventricular heart failure. The company's primary focus is the design, development, and eventual commercialization of a total artificial heart (TAH). This device is intended to provide a life-saving alternative for individuals who have exhausted all other medical and surgical options. Carmat's TAH is designed to mimic the function of a natural heart, providing both pulsatile flow and autoregulation, adapting to the patient's needs during rest and exercise. The company's geographic focus is currently in France and other international markets where it seeks regulatory approvals and partnerships for distribution. Carmat faces competition from established medical device companies that offer ventricular assist devices (VADs) and heart transplantation programs, but it differentiates itself with its total artificial heart technology, which aims to replace the entire failing heart.
What They Do
- Designs and develops total artificial hearts.
- Focuses on patients with end-stage biventricular heart failure.
- Offers a therapeutic alternative to heart transplantation.
- Develops devices that mimic the function of a natural heart.
- Provides pulsatile blood flow and autoregulation.
- Seeks regulatory approvals in France and internationally.
Business Model
- Develops and manufactures total artificial hearts.
- Seeks regulatory approvals for commercialization.
- Partners with hospitals and cardiac centers for device implantation.
- Generates revenue through sales of its artificial heart devices.
Industry Context
Carmat S.A. operates within the medical device industry, specifically targeting the cardiovascular device segment. This segment is characterized by continuous innovation, driven by the need for more effective treatments for heart failure and other cardiovascular diseases. The market for heart failure devices is expected to grow as the aging population increases and the prevalence of heart disease rises. Carmat competes with companies offering ventricular assist devices (VADs) and heart transplantation programs. The company's total artificial heart represents a novel approach with the potential to capture a significant share of the market if it demonstrates superior clinical outcomes.
Key Customers
- Patients with end-stage biventricular heart failure.
- Hospitals and cardiac centers.
- Cardiac surgeons.
Financials
Chart & Info
Carmat S.A. (CKMTF) stock price: Price data unavailable
Latest News
No recent news available for CKMTF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CKMTF.
Price Targets
Wall Street price target analysis for CKMTF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CKMTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Stephane Piat
Chief Executive Officer
Stephane Piat serves as the Chief Executive Officer of Carmat S.A. His background includes extensive experience in the medical device industry, with a focus on strategic leadership and commercialization. He has held various leadership positions in multinational healthcare companies, contributing to the development and launch of innovative medical technologies. His expertise spans across sales, marketing, and business development, providing him with a comprehensive understanding of the healthcare landscape. Piat's educational background includes advanced degrees in business and engineering.
Track Record: Under Stephane Piat's leadership, Carmat S.A. has focused on advancing its total artificial heart program through clinical trials and regulatory submissions. Key milestones include securing regulatory approvals in Europe and expanding the company's clinical trial program to new geographies. Piat has also overseen the development of strategic partnerships with leading hospitals and cardiac centers, contributing to the company's growth and market presence. His tenure has been marked by a commitment to innovation and patient-centric care.
CKMTF OTC Market Information
The OTC Other tier, where CKMTF trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to meet minimum listing standards, such as requirements for market capitalization, share price, or financial reporting. This lack of regulation increases the risk associated with investing in these companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low liquidity.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Higher price volatility.
- Verify the company's management team and their track record.
- Review any available financial statements and assess the company's financial health.
- Research the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings involving the company.
- Assess the company's long-term growth potential.
- Company has a functional website with contact information.
- Company has patents or other intellectual property.
- Company has partnerships with reputable organizations.
- Company has a clear business plan and strategy.
- Company has a management team with relevant experience.
Carmat S.A. Stock: Key Questions Answered
What does Carmat S.A. do?
Carmat S.A. specializes in the development and manufacturing of a total artificial heart designed to address end-stage biventricular heart failure. Their device aims to provide a viable alternative for patients who are not eligible for or cannot receive a heart transplant. Carmat's technology mimics the natural heart's function, offering pulsatile blood flow and autoregulation to adapt to the patient's needs. The company is currently focused on securing regulatory approvals and establishing partnerships to commercialize its artificial heart in key markets.
What do analysts say about CKMTF stock?
As of 2026-03-15, there is no readily available analyst consensus on CKMTF due to its OTC listing and limited coverage. The company's valuation is influenced by factors such as clinical trial outcomes, regulatory approvals, and commercialization progress. Investors should carefully consider the risks and uncertainties associated with investing in a pre-profitability medical device company operating in a highly regulated industry. Key metrics to monitor include clinical trial results, regulatory milestones, and revenue growth following commercial launch.
What are the main risks for CKMTF?
Investing in Carmat S.A. (CKMTF) carries significant risks inherent to the medical device industry and its OTC listing. These risks include the potential for clinical trial failures, regulatory setbacks, and competition from established medical device companies. The company's lack of profitability and reliance on future funding also pose financial risks. Furthermore, the OTC listing exposes investors to liquidity risks and potential price volatility. Investors should carefully assess these risks and conduct thorough due diligence before investing in CKMTF.
What are the key factors to evaluate for CKMTF?
Carmat S.A. (CKMTF) currently holds an AI score of 61/100, indicating moderate score. Key strength: Innovative total artificial heart technology.. Primary risk to monitor: Potential: Clinical trial failures or negative data could significantly impact the company's prospects.. This is not financial advice.
How frequently does CKMTF data refresh on this page?
CKMTF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CKMTF's recent stock price performance?
Recent price movement in Carmat S.A. (CKMTF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative total artificial heart technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CKMTF overvalued or undervalued right now?
Determining whether Carmat S.A. (CKMTF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CKMTF?
Before investing in Carmat S.A. (CKMTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.